genetic biomarker use in myeloma: updates from ash 2020
Published 3 years ago • 36 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
2:01
ctcs as a biomarker of tumor burden in multiple myeloma
-
3:00
current & emerging biomarkers in multiple myeloma
-
1:49
circulating tumor dna as a biomarker in multiple myeloma: pitfalls and future outlooks
-
1:38
the genomic definition of high-risk myeloma
-
0:52
novel strategies to evaluate biomarkers of interest in multiple myeloma
-
4:56
imeta | tiger: tumor immunotherapy gene expression data analysis r package
-
9:22
myeloma:interpreting test results | bmj learning
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
5:37
biomarkers in ultra low-risk myeloma
-
2:30
using biomarkers to identify molecular lesions and monitor response to treatment in multiple myeloma
-
10:20
the genomics of high-risk myeloma
-
1:17
the genetics of multiple myeloma and how we can use it to improve outcomes
-
2:37
meta-analysis of studies on biomarker-defined early multiple myeloma
-
2:17
mrd: a promising biomarker in multiple myeloma
-
1:05
ultrastratification of multiple myeloma via biomarkers
-
0:59
defining the origins of multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
1:02
circulating plasma cell levels as a prognostic biomarker in myeloma
-
2:16
analyzing genetic and epigenetic markers of high-risk multiple myeloma
-
1:52
subclonal evolution and cytogenetic aberrations in myeloma
-
2:24
the importance of molecular testing in multiple myeloma and how this may impact future treatment
-
2:30
biomarkers of cardiotoxicity in multiple myeloma